Search Results - "Van Doorn, M. B. A."

A systematic literature review of the human skin microbiome as biomarker for dermatological drug development by Niemeyer ‐ van der Kolk, T., Wall, H. E. C., Balmforth, C., Van Doorn, M. B. A., Rissmann, R.

“…Aims To explore the potential of the skin microbiome as biomarker in six dermatological conditions: atopic dermatitis (AD), acne vulgaris (AV), psoriasis…”
Get full text

Renal cancer and pneumothorax risk in Birt–Hogg–Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families by Houweling, A C, Gijezen, L M, Jonker, M A, van Doorn, M B A, Oldenburg, R A, van Spaendonck-Zwarts, K Y, Leter, E M, van Os, T A, van Grieken, N C T, Jaspars, E H, de Jong, M M, Bongers, E M H F, Johannesma, P C, Postmus, P E, van Moorselaar, R J A, van Waesberghe, J-Htm, Starink, T M, van Steensel, M A M, Gille, J J P, Menko, F H

“…Background: Birt–Hogg–Dubé (BHD) syndrome is an autosomal dominant condition caused by germline FLCN mutations, and characterised by fibrofolliculomas,…”
Get full text

Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision by de Vries, K., Greveling, K., Prens, L.M., Munte, K., Koljenović, S., van Doorn, M.B.A., Prens, E.P.

“…Summary Background Lentigo maligna is a slowly growing melanoma in situ. Current guidelines advise wide local excision with a margin of 5 mm as the treatment…”
Get full text

Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study by Soegiharto, R, Alizadeh Aghdam, M, Sørensen, J A, van Lindonk, E, Bulut Demir, F, Mohammad Porras, N, Matsuo, Y, Kiefer, L, Knulst, A C, Maurer, M, Ritchie, C, Rudenko, M, Kocatürk, E, Criado, R F J, Gregoriou, S, Bobylev, T, Kleinheinz, A, Takahagi, S, Hide, M, Giménez-Arnau, A M, Salman, A, Kara, R Oztas, Dikicier, B S, van Doorn, M B A, Thomsen, S F, van den Reek, J M P A, Röckmann, H

“…Long-term data on the effectiveness and safety of omalizumab for chronic inducible urticaria (CIndU) in large populations are lacking. To evaluate the…”
Get full text

Mobile e‐diary application facilitates the monitoring of patient‐reported outcomes and a high treatment adherence for clinical trials in dermatology by Rijsbergen, M., Niemeyer‐van der Kolk, T., Rijneveld, R., Pinckaers, J.H.F.M., Meshcheriakov, I., Bouwes Bavinck, J.N., van Doorn, M.B.A., Hogendoorn, G., Feiss, G., Cohen, A.F., Burggraaf, J., van Poelgeest, M.I.E., Rissmann, R.

“…Background Assessment of treatment effects in clinical trials requires valid information on treatment adherence, adverse events and symptoms. Paper‐based…”
Get full text

Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies by Carrascosa, J.-M., van Doorn, M.B.A., Lahfa, M., Nestle, F.O., Jullien, D., Prinz, J.C.

“…Biological drugs such as the tumour necrosis factor inhibitors have revolutionized the treatment of psoriasis, but some have the potential to induce an…”
Get full text

A two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod: excellent cosmesis, but frequent recurrences on the nose by Greveling, K., de Vries, K., van Doorn, M.B.A., Prens, E.P.

Get full text

Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers by Vossen, A.R.J.V., van der Zee, H.H., Davelaar, N., Mus, A.M.C., van Doorn, M.B.A., Prens, E.P.

“…Background Treatment with apremilast has recently demonstrated clinically meaningful improvement in moderate hidradenitis suppurativa (HS). Objective To…”
Get full text

Non‐invasive anaesthetic methods for dermatological laser procedures: a systematic review by Greveling, K., Prens, E.P., Liu, L., Doorn, M.B.A.

“…Pain is a common side‐effect of dermatological laser procedures. Non‐invasive anaesthetic drugs and anaesthetic procedures can be used to provide pain relief…”
Get full text

Lentigo maligna – anatomic location as a potential risk factor for recurrences after non‐surgical treatment by Greveling, K., Klok, Th, Doorn, M.B.A., Noordhoek Hegt, V., Prens, E.P.

“…Background A higher incidence of lentigo maligna (LM) recurrences on the nose was previously observed in our cohort after non‐surgical treatment. Objectives To…”
Get full text

Combining biologics with methotrexate in psoriasis: a systematic review by van Bezooijen, J.S., Prens, E.P., Pradeepti, M.S., Atiqi, R., Schreurs, M.W.J., Koch, B.C.P., van Gelder, T., van Doorn, M.B.A.

Get full text

A fistula in disguise- a case report by Smit, P., Wiryasaputra, D.C.M.S., van Doorn, M.B.A.

Get full text

MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers by Boot, J.D, De Haas, S.L, Van Gerven, J.M.A, De Smet, M, Leathem, T, Wagner, J, Denker, A, Miller, D, Van Doorn, M.B.A, Schoemaker, R.C, Cohen, A.F, Diamant, Z

“…Abstract Background MK-0873 is a novel selective phosphodiesterase-4 inhibitor, which has been in development for the treatment of chronic obstructive…”
Get full text

P725 Patients with Immune Mediated Inflammatory Diseases are insufficiently protected against vaccine-preventable influenza and pneumococcal infections due to low vaccination rates by Van De Pol, N, van der Woude, C J, Vis, M, van Doorn, M B A, Derikx, L A A P, Molendijk, I, de Vries, A C

Get full text

Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE) by de Visser, S.J., Uchida, N., van Vliet-Daskalopoulou, E., Fukazawa, I., van Doorn, M.B.A., van den Heuvel, M.W., Machielsen, C.S.M., Uchida, E., Cohen, A.F.

“…To compare the pharmacokinetic parameters and safety of the progestagen, Org 30659, (17α)-17-hydroxy-11-methylene-19-norpregna-4,15-dien-20-yn-3-one), and…”
Get full text

Blisters in disguise by Dowlatshahi, EA, Diercks, GFH, van Doorn, MBA

Get full text

P665 Cardiovascular risk profile in chronic auto-inflammatory diseases: a cross-sectional single center study by Sleutjes, J A M, Roeters van Lennep, J E, Verploegh, P J P, van Doorn, M B A, Vis, M, van der Woude, C J, de Vries, A C

Get full text

Age and fast initial response predict omalizumab retreatment in chronic urticaria by Meertens, M.A.J., Luijf, T., van Lindonk, E.A.M., Soegiharto, Reineke, Assil, S., Aghdam, M. Alizadeh, Kentie, P.A., Knulst, A.C., van Doorn, M.B.A., Röckmann, H.

Get full text

Adalimumab with methotrexate versus adalimumab monotherapy in psoriasis: First-year results of a single-blind randomized controlled trial by van der Kraaij, G E, Busard, C I, van den Reek, J, Menting, S P, Musters, A H, Hutten, B A, de Rie, M A, Ouwerkerk, W, van Bezooijen, J S, Prens, E, Rispens, T, de Vries, A, de Jong, E M G J, de Kort, W, Lambert, J, van Doorn, M B A, Spuls, Ph I

“…Adalimumab is normally prescribed with methotrexate (MTX) in rheumatoid arthritis given the enhanced treatment effect and reduced antidrug antibody (ADA)…”
Get full text

A man with severe skin rash by Nguyen, T V, van Rooijen, G L, van Doorn, M B A

“…A 31-year-old man visited the outpatient clinic Dermatology with an exacerbation of his atopic eczema. Since a few day vesicles and crusts had appeared and his…”
Get more information